Last Price
5.29
Today's Change
+1.90 (56.04%)
Day's Change
5.02 - 6.49
Trading Volume
31,883,292
Market Cap
43 Million
Shares Outstanding
8 Million
Avg Volume
293,190
Avg Price (50 Days)
5.54
Avg Price (200 Days)
6.44
PE Ratio
-0.05
EPS
-109.20
Earnings Announcement
07-Nov-2024
Previous Close
3.39
Open
6.27
Day's Range
5.02 - 6.49
Year Range
2.8 - 21.84
Trading Volume
31,895,596
1 Day Change
55.46%
5 Day Change
14.07%
1 Month Change
-11.58%
3 Month Change
-35.73%
6 Month Change
-19.66%
Ytd Change
-32.52%
1 Year Change
-76.14%
3 Year Change
-99.77%
5 Year Change
-99.77%
10 Year Change
-99.77%
Max Change
-99.77%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Onconetix, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.